- Home
- AMBI vs NLSP Comparison
AMBI vs NLSP Comparison
Compare AMBI & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMBI
- NLSP
- Stock Information
- Founded
- AMBI 1995
- NLSP 2015
- Country
- AMBI Brazil
- NLSP Switzerland
- Employees
- AMBI N/A
- NLSP N/A
- Industry
- AMBI Environmental Services
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- AMBI Industrials
- NLSP Health Care
- Exchange
- AMBI Nasdaq
- NLSP Nasdaq
- Market Cap
- AMBI 278.5M
- NLSP 12.4M
- IPO Year
- AMBI N/A
- NLSP 2021
- Fundamental
- Price
- AMBI $4.73
- NLSP $2.27
- Analyst Decision
- AMBI
- NLSP
- Analyst Count
- AMBI 0
- NLSP 0
- Target Price
- AMBI N/A
- NLSP N/A
- AVG Volume (30 Days)
- AMBI 13.1K
- NLSP 401.0K
- Earning Date
- AMBI 01-01-0001
- NLSP 07-15-2025
- Dividend Yield
- AMBI N/A
- NLSP N/A
- EPS Growth
- AMBI N/A
- NLSP N/A
- EPS
- AMBI N/A
- NLSP N/A
- Revenue
- AMBI $525,221,427.00
- NLSP N/A
- Revenue This Year
- AMBI N/A
- NLSP N/A
- Revenue Next Year
- AMBI N/A
- NLSP N/A
- P/E Ratio
- AMBI N/A
- NLSP N/A
- Revenue Growth
- AMBI 25.42
- NLSP N/A
- 52 Week Low
- AMBI $3.22
- NLSP $1.30
- 52 Week High
- AMBI $8.20
- NLSP $15.59
- Technical
- Relative Strength Index (RSI)
- AMBI 50.85
- NLSP 47.53
- Support Level
- AMBI $4.44
- NLSP $2.16
- Resistance Level
- AMBI $5.10
- NLSP $3.08
- Average True Range (ATR)
- AMBI 0.35
- NLSP 0.24
- MACD
- AMBI -0.00
- NLSP -0.03
- Stochastic Oscillator
- AMBI 50.57
- NLSP 11.67
About AMBI Ambipar Emergency Response
Ambipar Emergency Response is a environmental, emergency response and industrial field service provider in Brazil with presence in 16 countries in Latin America, North America, Europe, Africa and Antarctica. The company provides customers with a full suite of environmental services organized around prevention, training and emergency response on all transportation modes. The portfolio includes a broad variety of services such as environmental remediation, industrial field services, industrial cleaning of chemical and non-chemical products and of hazardous and non-hazardous waste, consulting services focused on accident prevention and environmental licensing.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.